In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputations.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 37665990.
- Also identified by DOI 10.7326/J23-0066.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Butt JH, Kondo T, Yang M, et al. <b>Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.</b> Eur Heart J. 2023;44:2170-2183. 37220172.
Medical subject headings
- Benzhydryl Compounds
- Heart Failure